Analyst Viewpoint
Unhealthy lifestyle habits and various genetic predispositions are driving the head and neck cancer market size. Rapid breakthroughs in radiation treatment and enhanced post-treatment rehabilitation are also boosting the demand for head and neck cancer treatment. High levels of air and environmental pollution, alongside genetic abnormalities resulting from the presence of toxic chemicals in the food chain have been associated with various health risks, including potential links to certain types of cancer.
Rise in investment in healthcare infrastructure in developing economies and growth in popularity of medical tourism are propelling the head and neck cancer market trajectory. Manufacturers are investing in the R&D of affordable treatment to expand their customer base.
Cancer develops when healthy cells mutate and expand uncontrollably, generating a mass known as a tumor. A tumor might be malignant or benign. A malignant tumor can multiply and spread to other sections of the body. A benign tumor can develop but does not spread. The term "head and neck cancer" refers to a variety of types of neck cancer that grow in or around the throat, larynx, nose, sinuses, and mouth.
The tumor can spread (metastasize) from the initial location to other body parts. Cancer is usually referred to by the site where it first appeared. Lung cancer that spreads to the liver, for example, is still referred to as lung cancer. Distinct forms of cancer have significantly different behaviors. They might develop at different speeds and react to various therapies. Thus, patients with cancer require treatment tailored to their specific form of disease.
Squamous cell carcinomas account for the majority of head and neck malignancies. This cancer starts in flat squamous cells. These cells form the thin layer of tissue that covers the structures in the head and neck. These structures contain mucosa beneath this layer, which is termed epithelium - a moist tissue present in the head and neck. Carcinoma in situ refers to a malignancy only located in the layer of squamous cells (epithelium), mostly presenting cancer in the neck area. If the disease has spread past this cell layer and into deeper tissue, it is called invasive squamous cell carcinoma. If physicians cannot pinpoint the disease's origin, it is referred to as cancer of unknown primary.
Tobacco (smoked or chewable), alcohol, areca nut, and malnutrition are all prevalent etiological variables that are also critical downstream socioeconomic determinants. Heavy smokers and drinkers are 35 times more likely to get head and neck cancer. Vitamin A, C, E, iron, selenium, and zinc deficits are also factors. Increased salt-preserved food consumption, grilled barbecued meat, and frozen and processed foods are all well-known etiological variables. Other contributing variables include exposure to air pollution, excessive sunshine, and other carcinogens. Clinical trials for HPV-positive head and neck cancer, as well as other specific viruses, such as HPV, EBV, Herpes, and HIV, have cemented in literature their role in causing cancer. Hence, unhealthy lifestyle habits are driving the head and neck cancer market.
Genetic abnormalities have been linked with the disease, though environmental variables play an essential role. People with a first-degree family history of head and neck cancer have a risk of 3.5-3.8, whereas persons with multiple primaries in the family have an eight-fold risk. Patients with a poor ability to metabolize toxins and a weakened immune system are around 500-700 times more likely to acquire malignant carcinomas. Rise in incidences of immune disorders and increase in influx of carcinogens into the body from the environment are projected to significantly influence the head and neck cancer market development in the near future.
Significant advances have been made in the Radiation Treatment (RT) of head and neck cancers over recent years. The introduction of multimodality imaging for target volume and organs at risk delineation and intensity-modulated RT has improved the efficacy of RT. The use of altered fractionation regimens and concurrent administration of chemotherapy for targeted areas have further enhanced the post-RT outcomes for patients. One such example is the massive strides made in speech therapy post-treatment for throat cancer. Overall, such advancements have resulted in improved locoregional control and overall survival probability, a reduction in the long-term harmful effects of RT, and a subsequent increase in quality of life. This, in turn, is fueling the head and neck cancer market value.
Further advancements in the treatment of head and neck cancer have resulted from improved integration of molecular imaging to detect tumor sub-volumes. These tumor groups often require more radiation doses and therapy adaptation to monitor changes in patient anatomy throughout treatment. In other cases, proton treatment produces even more precise dosage distribution, enhancing patient outcomes. Manufacturers in the head and neck cancer market are looking at further progress in this field by focusing on target volume and organ-at-risk delineation, molecular imaging for tumor delineation, dose painting for dose escalation, dose adaptability throughout treatment, and the possible benefit of proton therapy.
According to the latest head and neck cancer market trends, North America held largest share in 2022. Increase in prevalence of head and neck cancer, rise in healthcare expenditure, and expansion in pharmaceutical sector are fueling the market dynamics of the region. Presence of a robust product pipeline is also driving the global market statistics.
Rise in demand for effective medications for the treatment of head and neck cancer is boosting the market expansion in Asia Pacific. China and India are major markets for head and neck cancer treatment. Growth in pharmaceutical sector is also influencing the head and neck cancer market share in the region.
The industry in Latin America and Middle East & Africa is projected to grow at a steady pace during the forecast period. Surge in healthcare investment and rise in number of pharmaceutical firms operating locally are boosting the head and neck cancer market landscape in these regions.
Mergers & acquisitions, new product development, and strategic collaborations with government authorities are major strategies adopted by key players. Manufacturers are introducing innovative drugs and therapy modalities with a focus on improved quality of life for patients. Regulatory support has also enabled businesses to develop a large pipeline of drugs, greatly enhancing the prospects of finding better treatment than the modalities currently available in this landscape.
Major players operating in the global head and neck cancer industry include Sanofi, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche, AstraZeneca, Merck KgaA, Bayer AG, Bristol-Myers Squibb Company, Bayer AG, Galera, Fresenius Kabi, and Teva Pharmaceuticals.
Each of these players has been profiled in the head and neck cancer market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 1.6 Bn |
| Market Forecast Value in 2031 | US$ 2.9 Bn |
| Growth Rate (CAGR) | 6.8% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape | Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022 Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview) |
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 1.6 Bn in 2022
It is likely to grow at a CAGR of 6.8% from 2023 to 2031
Unhealthy lifestyle habits and various genetic predispositions along with rapid breakthroughs in radiation treatment and enhanced post-treatment rehabilitation
The hospital pharmacies segment held the largest share in 2022
North America was the leading region in 2022
Sanofi, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche, AstraZeneca, Merck KgaA, Bayer AG, Bristol-Myers Squibb Company, Galera, Fresenius Kabi, and Teva Pharmaceuticals
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Head and Neck Cancer Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Head and Neck Cancer Market Analysis and Forecasts, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. EGFR Inhibitors
6.3.2. Mitotic Inhibitors
6.3.3. Anti-PD-1 Monoclonal Antibodies
6.3.4. Others
6.4. Market Attractiveness, by Drug Class
7. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospitals Pharmacies
7.3.2. Retail Pharmacies
7.3.3. E-commerce
7.4. Market Attractiveness, by Distribution Channel
8. Global Head and Neck Cancer Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Head and Neck Cancer Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017–2031
9.2.1. EGFR Inhibitors
9.2.2. Mitotic Inhibitors
9.2.3. Anti-PD-1 Monoclonal Antibodies
9.2.4. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospitals Pharmacies
9.3.2. Retail Pharmacies
9.3.3. E-commerce
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Head and Neck Cancer Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. EGFR Inhibitors
10.2.2. Mitotic Inhibitors
10.2.3. Anti-PD-1 Monoclonal Antibodies
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospitals Pharmacies
10.3.2. Retail Pharmacies
10.3.3. E-commerce
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Head and Neck Cancer Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. EGFR Inhibitors
11.2.2. Mitotic Inhibitors
11.2.3. Anti-PD-1 Monoclonal Antibodies
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospitals Pharmacies
11.3.2. Retail Pharmacies
11.3.3. E-commerce
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Head and Neck Cancer Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. EGFR Inhibitors
12.2.2. Mitotic Inhibitors
12.2.3. Anti-PD-1 Monoclonal Antibodies
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospitals Pharmacies
12.3.2. Retail Pharmacies
12.3.3. E-commerce
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Head and Neck Cancer Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. EGFR Inhibitors
13.2.2. Mitotic Inhibitors
13.2.3. Anti-PD-1 Monoclonal Antibodies
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospitals Pharmacies
13.3.2. Retail Pharmacies
13.3.3. E-commerce
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Sanofi
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Eli Lilly and Company
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. F. Hoffman-La Roche
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. AstraZeneca
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Merck KgaA
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Bayer AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Bristol-Myers Squibb Company
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Galera
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Fresenius Kabi
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Teva Pharmaceuticals
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. Financial Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
List of Tables
Table 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 2: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 3: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 4: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 5: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 6: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 7: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 8: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 9: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 10: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 12: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 16: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 18: Middle East & Africa Head and Neck Cancer Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
List of Figures
Figure 1: Global Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031
Figure 2: Global Head and Neck Cancer Market Value Share, by Drug Class, 2022
Figure 3: Global Head and Neck Cancer Market Value Share, by Distribution Channel, 2022
Figure 4: Global Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 5: Global Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 6: Global Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 7: Global Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 8: Global Head and Neck Cancer Market Value Share Analysis, by Region, 2022 and 2031
Figure 9: Global Head and Neck Cancer Market Attractiveness Analysis, by Region, 2023–2031
Figure 10: North America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: North America Head and Neck Cancer Market Value Share Analysis, by Country, 2022 and 2031
Figure 12: North America Head and Neck Cancer Market Attractiveness Analysis, by Country, 2023–2031
Figure 13: North America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 14: North America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 15: North America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 16: North America Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 17: Europe Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031
Figure 18: Europe Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 19: Europe Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 20: Europe Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 21: Europe America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 22: Europe Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 23: Europe Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 24: Asia Pacific Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031
Figure 25: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 26: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 27: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 28: Asia Pacific America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 29: Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 30: Asia Pacific Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 31: Latin America Head and Neck Cancer Market Value (US$ Mn) Forecast, 2017–2031
Figure 32: Latin America Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 34: Latin America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 35: Latin America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 36: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 37: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Middle East & Africa America Head and Neck Cancer Market Value Share Analysis, by Drug Class, 2022–2031
Figure 39: Middle East & Africa America Head and Neck Cancer Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 40: Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 41: Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 42: Global Head and Neck Cancer Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Head and Neck Cancer Market
